BioNexus Gene Lab Corp Files 8-K
Ticker: BGLC · Form: 8-K · Filed: Dec 23, 2025 · CIK: 1737523
| Field | Detail |
|---|---|
| Company | Bionexus Gene Lab CORP (BGLC) |
| Form Type | 8-K |
| Filed Date | Dec 23, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, other-events
TL;DR
BioNexus Gene Lab Corp. filed an 8-K on 12/23/25 for an event on 12/19/25. Details pending.
AI Summary
BioNexus Gene Lab Corp. filed an 8-K on December 23, 2025, reporting an event that occurred on December 19, 2025. The filing is categorized under 'Other Events' and does not specify any material agreements, acquisitions, or executive changes.
Why It Matters
This filing indicates a corporate event has been reported by BioNexus Gene Lab Corp., requiring investors to check the details for any significant developments.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' without immediate disclosed material impact.
Key Players & Entities
- BioNexus Gene Lab Corp. (company) — Filer of the 8-K report
- December 19, 2025 (date) — Earliest event date reported
- December 23, 2025 (date) — Filing date of the 8-K
- Wyoming (jurisdiction) — State of incorporation
FAQ
What specific event is reported under 'Other Events' in this 8-K filing?
The filing does not specify the exact nature of the 'Other Events' beyond the general categorization.
When was the earliest event reported in the filing?
The earliest event reported in the filing occurred on December 19, 2025.
What is the filing date of this 8-K?
This 8-K was filed on December 23, 2025.
What is the state of incorporation for BioNexus Gene Lab Corp.?
BioNexus Gene Lab Corp. is incorporated in Wyoming.
What is the principal executive office address for BioNexus Gene Lab Corp.?
The principal executive office is located at Unit A-28-7, Tower A, Menara UOA Bangsar, No.5 Jln Bangsar Utama 1, 59000 Kuala Lumpur.
Filing Stats: 655 words · 3 min read · ~2 pages · Grade level 12.7 · Accepted 2025-12-23 17:20:34
Filing Documents
- bglc_8k.htm (8-K) — 25KB
- 0001477932-25-009186.txt ( ) — 141KB
- bglc-20251219.xsd (EX-101.SCH) — 5KB
- bglc-20251219_lab.xml (EX-101.LAB) — 15KB
- bglc-20251219_cal.xml (EX-101.CAL) — 1KB
- bglc-20251219_pre.xml (EX-101.PRE) — 9KB
- bglc-20251219_def.xml (EX-101.DEF) — 2KB
- bglc_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events As previously disclosed, commencing in the third quarter of fiscal year 2025, the Company's Board of Directors authorized the evaluation of a potential expansion into Contract Development and Manufacturing ("CDMO") activities within its Chemrex Corporation Sdn. Bhd. ("Chemrex") subsidiary. This evaluation formed part of a broader business rationalization initiative in light of challenges identified in Chemrex's legacy operations, its business outlook, and the Company's strategic objective of transitioning toward biotechnology-focused development activities. The Company has also previously disclosed that it initiated a governance review of Chemrex, which includes an assessment of historical governance, compliance, and operational matters. This review remains ongoing and is being conducted as part of the Company's efforts to enhance oversight, internal controls, and governance practices within the Chemrex subsidiary. In connection with this governance review and the regularisation of Chemrex's board and management structure, the Company appointed additional directors to the board of Chemrex to oversee these efforts. The reconstituted board of directors of Chemrex appointed Mr. Matthew L. Barsing to serve as a director and as Chairman of the Board of Chemrex. Mr. Barsing has prior experience in public-sector and private-sector leadership roles, including service with the Malaysian Digital Economy Corporation and executive leadership roles within technology-focused enterprises. On December 19, 2025, the Company received notices of resignation from the following officers and directors of Chemrex: Mr. Too Kam Tham Mr. Liong Tai Tan Mr. Wei Foong Lim Mr. Kuan Yew Tan @ Hing Kuan Yew These individuals did not serve as executive officers of the Company. At this time, the Company continues to evaluate the impact of these resignations in the context of the ongoing governance review and, where appropriate, to assess any potential courses of ac
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioNexus Gene Lab Corp. /s/ Su-Leng Tan Lee By: Su-Leng Tan Lee Chief Executive Officer Date: December 23, 2025 3